Prolocor and Slingshot Biosciences Announce Publication of ‘Assessing Prognosis by Quantifying FcγRIIa on Fixed Platelets’ in Bioanalysis
The Prolocor pFCG® test measures the expression of a specific protein on the platelet surface which this study demonstrates is a reliable prognostic tool to...
CARDIO inCode-Score Clinical Publication on Polygenic Risk of Coronary Heart Disease
US Study Publication in the American Journal of Preventive Cardiology GENinCode Plc (www.genincode.com) the polygenics company focused on the prevention of cardiovascular disease and ovarian...
Prolocor Announces Appointment of Raymond Russo as Chief Commercial Officer
Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa (pFCG test),...
Prolocor Announces $1.7 Million in Bridge Funding
Green Park & Golf Ventures and Labcorp continue to demonstrate ongoing commitment to Prolocor initiatives.Funding will be used for ongoing clinical program and commercialization in...
Prolocor to Present New Clinical Evidence at ACC 24 Supporting the Use of PLATELET FCɣRIIA (PFCG) as a Key Tool in Individualizing Dual Antiplatelet Therapy (DAPT)
Date April 6, 2024, Location Hall B4-5Abstract 1307-159 / 159ASSOCIATION BETWEEN PROGNOSTIC IMPLICATIONS OF PLATELET FCɣRIIA (PFCG) AND TREATMENT STRATEGY FOR MYOCARDIAL INFARCTION Prolocor, Inc.,...
CARDIO inCode Study Results Presented at ESC Annual Meeting
Coronary Heart Disease (CHD) prevention nearly twice as effective when using CARDIO inCode as method to target treatment GENinCode Plc (AIM - GENI), the polygenics...
Biotricity’s Founder & CEO Waqaas Al-Siddiq to Present at World Heart Summit May 19-21 in Geneva, Switzerland
Dr. Waqaas will address, meet with, world leaders and medical innovators on pressing challenges and solutions in global cardiovascular health, digital health and AIREDWOOD CITY,...